Resources

AVAC’s Resource Database contains educational and advocacy materials covering a wide range of issues on biomedical prevention of HIV, STIs, COVID-19 and emerging health threats—from research to rollout.

To search for clinical trials and detailed information on products in development, visit our Prevention Research & Development Database

Results

showing 1-10 of 872

Spotlight on MPTs Addressing STIs

This graphic outlines the development journey of multipurpose technologies (MPTs) that guard against STIs, including HIV, while also preventing pregnancy. It tracks the advancement of various potential products through different trial stages, emphasizing their combined protective roles.

July 2024


MPT R&D Funding 2018-2021

This graphic tracks funding levels for a variety of multipurpose technologies for several years.

July 2024


At A Glance: The MPT R&D Pipeline

This graphic shows the status of products in development.

July 2024


PxPulse: The Advocacy Chronicles with Ruth Akulu

In this episode, we explore advocacy efforts in Uganda for the Dual Prevention Pill (DPP), a new product that combines oral PrEP and contraception. Discover why the DPP is essential for young women and HIV prevention, and learn about the challenges faced in promoting its use.

July 2024


Advocates’ Guide to Multipurpose Prevention Technologies (MPTs)

Multipurpose prevention technologies (MPTs) are products designed to simultaneously address more than one sexual and reproductive health concern. This advocates’ guide shows the pipeline of products in development, discusses why MPTs are needed, investment, and what advocates can do to push for MPT development and introduction.

July 2024


PrEP Justice

In a major twist that could potentially result in as much as $1B for equitable PrEP access in the US, the government has just made the decision to appeal last year’s jury verdict in the US v. Gilead case. The Choice Agenda and PrEP4All discussed the origin of US v. Gilead, the reasons for the government appeal, and what the case means for PrEP users in the United States.

Prevention Option:

July 2024


The Future of ARV-Based Prevention and More

The pipeline of non-vaccine HIV prevention products includes oral pills, vaginal rings, vaginal and rectal gels, vaginal films, long-acting injectable antiretrovirals and more. Also pictured are the range of MPTs in development that aim to reduce the risk of HIV and STIs and/or provide effective contraception for women.

Prevention Option:

July 2024


AVAC’s Guide to AIDS 2024 in Munich

The AIDS 2024 conference occurs on the heels of the PURPOSE 1 PrEP trial announcement. AVAC will be tracking discussion and debate on how to make the full range of PrEP products feasible choices for all people who need and want HIV prevention. We’ll also be following the latest scientific advances, efforts in decolonizing global health, successes in community-led initiatives, and more.

July 2024


The Lens on LEN

In late June 2024, Gilead Sciences announced an early review of the data of the PURPOSE 1 trial by an
independent monitoring board, which found that injectable lenacapavir (LEN) provided as prevention
was safe and highly effective against HIV. No infections were seen among trial participants those receiving LEN. This advocates’ primer provides further background on the product and trials, raises key questions, and explores next steps.

Prevention Option:

July 2024


Global HIV Prevention Advocates Call for Accelerated Timeline for Widespread Access to Injectable Lenacapavir for PrEP

A global cadre of HIV prevention advocates is calling for an accelerated timeline for access to the HIV prevention drug lenacapavir. Gilead, the developer of the drug, announced topline results from a large study among cisgender African women on 20 June, followed shortly thereafter with a statement about access.

Prevention Option:

July 2024


showing 1-10 of 872